Gastric Cancer
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 21, 2006; 12(7): 1005-1012
Published online Feb 21, 2006. doi: 10.3748/wjg.v12.i7.1005
Table 1 Correlation of staining with clinicopathologic data
Clinicopathologic featuresaiNOSbNo. of casesTotal positive (%)NTYRbNo. of casesTotal positive (%)8OH-dGbNo. of casesTotal positive (%)
Infiltrative cancer subtypes85 35 (41)65 40 (62)82 41 (50)
TC54 291 (541)43 312 ( 722)54 28 (52)
DC17 31 ( 181)12 6 (50)14 7 (50)
PolyC14 31 (211)10 32 ( 302)14 6 (43)
Intraepithelial cancer
Periinfiltrative cancer5 3 (60)6 4 (67)6 4 (67)
Without infiltrative cancer7 1 (14)7 6 (86)10 5 (50)
Topography of infiltrative cancer
Cardia10 4 (40)7 3 (43)11 5 (45)
Gastric stump12 6 (50)9 5 (56)8 3 (38)
Antrum with angulus+pylorus45 18 (40)35 22 (63)41 22 (54)
Body14 7 (50)11 9 (82)15 11 (73)
Peritumorous mucosa
Adjacent: N + no IM G15 5 (33)23 9 (39)30 10 (33)
Adjacent: atrophy IM23 14 (61)21 10 (48)26 18 (69)
At distance: N + no IM G3 1 (33)6 1 (17)5 2 (40)
At distance: atrophy IM7 4 (57)7 5 (71)13 9 (69)
Adjacent+distant: N + no IM G`18 6 (33)29 10 (34)35 123 (343)
Adjacent+distant: atrophy IM30 18 (60)28 15 (54)39 27 (69)
Precancerous lesions
Low grade dysplasia13 9 (69)14 11 (79)17 143 (823)
Atrophy IM without cancer10 8 (80)7 7 (100)11 6 (55)
Atrophy IM with + without cancer40 26 (65)35 22 (63)50 333 (663)
H pylori infection
Negative68 27 (40)54 35 (65)77 41 (53)
Positive18 7 (39)13 7 (54)16 9 (56)
Sex
Male60 28 (47)50 32 (64)66 36 (55)
Female30 8 (27)29 20 (69)35 18 (51)
Table 2 Correlation of staining with pTNM pathological classificationa
Pathological classificationbiNOScNo. of casesTotal positive (%)NTYRcNo. of casesTotal positive (%)8OH-dGcNo. of casesTotal positive (%)
pTis7 1 (14)7 6 (86)10 5 (50)
pT118 7 (39)16 12 (75)16 10 (63)
TC13 7 (54)12 9 (75)12 8 (67)
DC3 0 (0)2 2 (100)2 2 (100)
PolyC2 0 (0)2 1 (50)2 0 (0)
pT27 3 (43)8 6 (75)8 4 (50)
TC5 2 (40)6 5 (83)6 3 (50)
DC0 0 (0)0 0 (0)0 0 (0)
PolyC2 1 (50)2 1 (50)2 1 (50)
pT3/T422 9 (41)15 8 (53)21 10 (48)
TC12 7 (58)8 6 (75)12 6 (50)
DC5 1 (20)3 1 (33)4 2 (50)
PolyC5 1 (20)4 1 (25)5 2 (40)
pN020 10 (50)20 14 (70)20 11 (55)
TC16 8 (50)16 13 (81)16 10 (63)
DC1 1 (100)1 0 (0)1 1 (100)
PolyC3 1 (33)3 1 (33)3 0 (0)
pN+24 8 (33)17 9 (53)22 11 (50)
TC10 6 (60)7 4 (57)10 4 (40)
DC7 0 (0)5 3 (60)5 3 (60)
PolyC7 2 (29)5 2 (40)7 4 (57)
pM038 14 (37)3 21 (64)36 20 (56)
TC25 12 (48)2 17 (77)25 15 (60)
DC6 1 (17)4 2 (50)4 4 (100)
PolyC7 1 (14)7 2 (29)7 1 (14)
pM116 9 (56)12 8 (67)16 8 (50)
TC9 7 (78)8 6 (75)9 5 (56)
DC4 0 (0)3 2 (67)4 1 (25)
PolyC3 2 (67)1 0 (0)3 2 (67)
Table 3 Correlation of staining with stage groupinga
StagesbiNOScNo. of casesTotal positive(%)NTYRcNo. of casesTotal positive (%)8OH-dGcNo. of casesTotal positive (%)
Stage 07 1 (14)7 6 (86)10 5 (50)
Stage I22 9 (41)21 15 (71)21 12 (57)
TC16 8 (50)16 12 (75)16 10 (63)
DC3 0 (0)2 2 (100)2 2 (100)
PolyC3 1 (33)3 1 (33)3 0 (0)
Stage II+III13 5 (38)10 4 (40)12 5 (42)
TC8 4 (50)5 4 (80)7 3 (43)
DC2 1 (50)2 0 (0)2 2 (100)
PolyC3 0 (0)3 0 (0)3 0 (0)
Stage IV19 9 (47)14 10 (71)18 10 (56)
TC9 7 (78)8 6 (75)9 5 (56)
DC5 0 (0)3 2 (67)4 1 (25)
PolyC5 2 (40)3 2 (67)5 4 (80)
All stages (early cancer excluded)36 16 (44)29 17 (59)35 17 (49)
TC20 12 (60)17 13 (76)20 10 (50)
DC7 1 (14)5 2 (40)6 3 (50)
DC+PolyC16 4 (25)12 4 (33)15 7 (47)
Early cancer (pTis + pT1)25 8 (32)23 18 (78)26 15 (58)
TC20 8 (40)19 15 (79)22 13 (59)
DC3 0 (0)2 2 (100)2 2 (100)
DC+PolyC5 0 (0)4 3 (75)4 2 (50)
Table 4 Co-occurrence of immunostaining for iNOS, NTYR and 8-OH-dGa
MarkersNo. of samples (%)
TCbn = 40DCbn  = 12PolyCbn  = 10
All negative5 (12)2 (16)5 (50)
One positive
iNOS2 (5)1 (8)1 (10)
NTYR4 (10)2 (17)1 (10)
8-OHdG2 (5)2 (17)1 (10)
Two positive
iNOS + NTYR8 (20)1 (8)0 (0)
NTYR + 8-OHdG8 (20)3 (25)2 (20)
iNOS + 8-OHdG1 (2.5)1 (8)0 (0)
All positive
iNOS + NTYR + 8-OHdG10 (25)0 (0)0 (0)